Complex | |
AACDB_ID: | 5825 |
PDBID: | 8AOM |
Chains: | V_A |
Organism: | Homo sapiens, Lama glama |
Method: | XRD |
Resolution (Å): | 2.20 |
Reference: | 10.1016/j.jbc.2022.102769 |
Antibody | |
Antibody: | VHH6 VHH |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | Human programmed cell death 1 ligand 1 (PD-L1) D1 D2 |
Antigen mutation: | No |
Durg Target: | Q9NZQ7 |
Antibody
Chain: V
Mutation: NULL
>8AOM_V|Chain B[auth V]|VHH6|Lama glama (9844) GEVQLVESGGGLVQAGGSLRLSCAASGSISSRDVMRWYRQAPGKQRELVASISSGGGTYYVDSVKGRFTISRDNAENTLYLQMNSLKPEDTAVYYCWDLGHRPYFKDYWGQGTQVTVSS |
Antigen
Chain: A
Mutation: NULL
>8AOM_A|Chain A|Programmed cell death 1 ligand 1|Homo sapiens (9606) MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERT |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
V: ARG31 VAL33 ARG35 TYR37 LEU47 SER50 SER52 SER53 GLY54 GLY56 THR57 TYR58 TRP96 LEU98 HIS100 TYR103 PHE104 LYS105 ASP106 A: ALA51 ALA52 ILE54 TYR56 GLU58 GLN66 VAL68 HIS69 ASP73 VAL76 ARG113 MET115 ILE116 SER117 GLY120 ALA121 ASP122 TYR123 ARG125 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)